Pacific Biosciences CEO Mark van Oene sells $30,409 in stock

Pacific Biosciences of California CEO Mark van Oene sold 26,911 shares of the company's stock on August 17, 2026. The sale amounted to $30,409, with shares exchanged at a weighted average price of $1.13, falling between $1.13 and $1.15 per share. The transaction occurred as PACB stock hovers around its 52-week low of $1.07, marking a 39% decrease year-to-date.

Currently, the stock is trading at $1.14, a substantial drop from its 52-week high of $2.73. This sale was necessary to satisfy tax withholding requirements related to the vesting of restricted stock units. As a result of this transaction, Mr. Van Oene now owns 2,705,853 shares of Pacific Biosciences common stock.

Investors looking for additional insights into PACB may find value in InvestingPro's 7 exclusive tips and comprehensive Pro Research Reports on this stock and 1,400+ other US equities. Separately, PacBio's latest earnings report for Q2 2026 showed revenue of $39.0 million and an adjusted loss of $0.14 per share, both falling short of Wall Street's expectations.

The company also adjusted its full-year guidance, stating that achieving cash flow breakeven will be delayed beyond initial projections. Despite these setbacks, PacBio's revenue remained largely unchanged compared to the prior year.